The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; 28 of the 36 sources its claims cite were checked for support.
PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma
Open accessAbstract
BACKGROUND: Advanced clear cell renal cell carcinoma (ccRCC) carries a dismal prognosis, urging the discovery of novel therapeutic targets. Here, we investigate the uncharacterized protein PPP1R18 as a potential driver of ccRCC malignancy. METHODS: PPP1R18 expression and its prognostic value were evaluated using TCGA, GEO, and CPTAC databases, with validation in clinical samples and cell lines. The biological functions of PPP1R18 were assessed in vitro using siRNA-mediated knockdown in a series of in vitro assays and an in vivo xenograft model. The underlying molecular mechanisms were explored through bioinformatic analysis, Western blotting, and rescue experiments using specific pathway agonists and inhibitors to delineate the signaling cascade. RESULTS: PPP1R18 is significantly upregulated in ccRCC and serves as a robust independent predictor of poor survival. Knockdown of PPP1R18 substantially impaired ccRCC cell proliferation, migration, and invasion in vitro and suppressed tumor growth in vivo. Mechanistically, PPP1R18 depletion suppressed the phosphorylation of ERK and inhibited the Wnt/β-catenin pathway, leading to a reversal of the epithelial-mesenchymal transition (EMT) phenotype. Notably, activation of the ERK pathway rescued the inhibitory effects of PPP1R18 knockdown on Wnt/β-catenin signaling and malignant phenotypes. This rescue was subsequently abrogated by a Wnt/β-catenin inhibitor, confirming that Wnt/β-catenin acts downstream of the PPP1R18/ERK axis. CONCLUSION: PPP1R18 is a crucial oncogenic driver and prognostic biomarker in ccRCC. It promotes malignant phenotypes by activating the novel ERK/Wnt/β-catenin signaling axis, offering a potential new target for ccRCC treatment.
Overview
CoChat Summary
TL;DR
PPP1R18 is upregulated in clear cell renal cell carcinoma (ccRCC), predicts poor survival, and promotes proliferation, migration, invasion, and tumor growth. Mechanistically, PPP1R18 acts through an ERK-dependent Wnt/β-catenin pathway that induces EMT.
Key findings
- PPP1R18 was significantly upregulated in ccRCC across public datasets: TCGA-KIRC (539 tumors vs. 72 normal, P < 0.001), GSE167093 (254 pairs), GSE40435 (101 pairs), and CPTAC protein data (219 ccRCC vs. 169 normal); validation showed higher PPP1R18 protein in ccRCC cell lines and in 20 paired clinical specimens.
- High PPP1R18 expression was associated with advanced T stage (OR = 1.54, 95% CI 1.08–2.20), distant metastasis (OR = 1.90, 95% CI 1.16–3.12), advanced pathological stage (OR = 1.56, 95% CI 1.10–2.21), and higher histological grade (OR = 2.26, 95% CI 1.35–3.77); it predicted shorter OS (HR = 1.63, 95% CI 1.20–2.20), DSS (HR = 2.42, 95% CI 1.65–3.53), and PFI (HR = 1.73, 95% CI 1.26–2.37).
- PPP1R18 knockdown impaired ccRCC cell proliferation, migration, and invasion in vitro and suppressed tumor growth in vivo; re-expression of siRNA-resistant PPP1R18 restored these malignant phenotypes.
- PPP1R18 depletion suppressed ERK phosphorylation and Wnt/β-catenin signaling (decreased total/nuclear β-catenin, c-Myc, Cyclin D1) and reversed EMT markers (increased E-cadherin; decreased N-cadherin and vimentin); the ERK agonist PAF(C-16) rescued these effects, while the Wnt/β-catenin inhibitor XAV-939 abrogated the rescue.
Methods
- Bioinformatic analysis used TCGA-KIRC, GEO datasets GSE167093 and GSE40435, and UALCAN/CPTAC proteomic data; DEGs, GO/KEGG, and GSEA were analyzed in R.
- In vitro experiments used ccRCC cell lines 786-O, Caki-1, and OSRC-2 and normal renal cell lines HEK-293 and HK-2, with siRNA-mediated PPP1R18 knockdown, siRNA-resistant PPP1R18 rescue, Western blotting, CCK-8, wound healing, and Transwell assays.
- In vivo work used a subcutaneous xenograft model in male NDG mice (5 weeks old; n = 10, 5 per group) with 786-O cells stably expressing sh-PPP1R18 or sh-NC; tumors were measured every 3 days, excised after 3 weeks, and analyzed by IHC and Western blotting. Clinical validation included 20 paired ccRCC/adjacent tissues and 5 selected high-PPP1R18 pairs for pathway Western blots.
Limitations
- The paper states that the tumor microenvironment is complex and that further studies, including syngeneic or pharmacological inhibition models targeting Wnt/β-catenin in vivo, are needed.
- The paper states that the precise molecular mechanism by which PPP1R18 activates ERK remains to be fully elucidated.
- The paper states that PPP1R18’s clinical utility as a prognostic biomarker requires validation in large-scale, prospective, multi-center cohort studies; evident from the text, the clinical pathway validation used only 5 selected paired specimens.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
10 Valid · 0 Not valid · 1 Not checked · 92 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As c-Myc and Cyclin D1 are key drivers of cell proliferation, this directly links the PPP1R18/ERK/Wnt/β-catenin axis to the proliferative phenotype of ccRCC [56–58].”
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Discussion
What the sources say
- Partly supportedcites [56] Kruck S, Eyrich C, Scharpf M, Sievert K-D, Fend F, Stenzl A, Bedke J. Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int J Mol Sci. 2013;14:10944–57. https://doi.org/10.3390/ijms140610944. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) identifies c-myc and cyclin D1 as Wnt/β-catenin target genes and says Wnt1 increases proliferation. It does not establish a PPP1R18/ERK/Wnt/β-catenin axis or directly link that full axis to proliferation in ccRCC; the Conclusions (page not provided) also say the proposed nuclear activation of oncogenes was not demonstrated in these patient samples. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [57] Bretones G, Delgado MD, León J. Myc and cell cycle control. Biochim Biophys Acta. 2015;1849:506–16. https://doi.org/10.1016/j.bbagrm.2014.03.013. source
- Not checked — no full text of the sourcecites [58] Sherr CJ. Cancer cell cycles. Sci (New York NY). 1996;274:1672–7. https://pubmed.ncbi.nlm.nih.gov/8939849. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The crosstalk between the ERK and Wnt/β-catenin pathways, while reported in other cancers, has not been previously described in ccRCC, particularly under the regulation of PPP1R18”
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Discussion
What the sources say
- Partly supportedcites [41] Jeong W-J, Ro EJ, Choi K-Y. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway. NPJ Precision Oncol. 2018;2:5. https://doi.org/10.1038/s41698-018-0049-y. sourceExperimental — accuracy not yet measured
The Introduction and the section on colorectal tumorigenesis describe Wnt/β-catenin–RAS-ERK crosstalk in colorectal cancer and other cancer models (page numbers unavailable). The paper does not address ccRCC or PPP1R18, so it does not support the claim that this crosstalk had not previously been described in ccRCC under PPP1R18 regulation. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [42] Lee S-K, Hwang J-H, Choi K-Y. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis. Adv Biol Regul. 2018;68:46–54. https://doi.org/10.1016/j.jbior.2018.01.001. source
- Partly supportedcites [43] Gajos-Michniewicz A, Czyz M. WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. Genes Dis. 2024;11:727–46. https://doi.org/10.1016/j.gendis.2023.02.050. sourceExperimental — accuracy not yet measured
The section on pathways interacting with WNT/β-catenin signaling in HCC describes EGFR signaling through the RAS/RAF/MEK/ERK cascade promoting β-catenin signaling. That supports the sentence’s point that the pathways interact in another cancer, but the paper does not establish that such crosstalk had not previously been described in ccRCC or address its regulation by PPP1R18. (LLM, conf=0.88)
- Partly supportedcites [44] Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, et al. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell. 2009;36:547–59. https://doi.org/10.1016/j.molcel.2009.09.034. sourceExperimental — accuracy not yet measured
The Abstract and Discussion describe ERK-mediated activation of β-catenin signaling in tumor cells, with evidence from human glioblastoma specimens. They support the statement that this interplay has been reported in other cancers, but do not address ccRCC or PPP1R18 and cannot establish the claimed absence of prior reports in that setting. (LLM, conf=0.85)
- Supportedcites [45] Wang Y, Wang X, Wang K, Qi J, Zhang Y, Wang X, Zhang L, Zhou Y, Gu L, Yu R, Zhou X. Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop. J Experimental Clin Cancer Research: CR. 2023;42:161. https://doi.org/10.1186/s13046-023-02728-8. source
The Results section, “ERK is the core mediator between DRD2 and Wnt/β-catenin signaling,” reports that DRD2–ERK facilitates Wnt/β-catenin activation in glioblastoma. This supports the cited sentence’s reference to pathway crosstalk in another cancer; the statement about its novelty in ccRCC under PPP1R18 is the citing authors’ framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“PPP1R18 is significantly upregulated in ccRCC tissues and cell lines”
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Discussion
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As expected, treatment with the ERK agonist PAF(C-16) rescued the proliferation, migration, and invasion abilities of PPP1R18-knockdown cells (Fig. 6A-C).”
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Results > Activation of the ERK/Wnt/β-catenin axis is essential for PPP1R18-mediated ccRCC progression
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Fig. 4D, exogenous expression of PPP1R18si−res effectively restored the protein levels of total and nuclear β-catenin, along with its downstream effectors c-Myc and Cyclin D1.”
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Results > PPP1R18 promotes EMT and activates the Wnt/β-catenin signaling pathway
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
66 more claims
Create a free account to see all 103 claims and every source verdict.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 14
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Results > High PPP1R18 expression correlates with aggressive clinicopathological features and poor prognosis
“Moreover, in univariate Cox regression analysis, high PPP1R18 expression emerged as an independent prognostic factor for OS (Table 2).”
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Results > High PPP1R18 expression correlates with aggressive clinicopathological features and poor prognosis
“| PPP1R18 | 541 | 1.444 (1.155–1.806) | 0.001 | | 1.315 (0.931–1.856) | 0.120 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Materials and methods > Bioinformatic analysis
“The TCGA-KIRC dataset included 539 ccRCC and 72 normal tissue samples.”
§ PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma > Results > High PPP1R18 expression correlates with aggressive clinicopathological features and poor prognosis
“| PPP1R18 | 541 | 1.444 (1.155–1.806) | 0.001 | | 1.315 (0.931–1.856) | 0.120 |”
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“5.1.symbols.gmt) as the reference [24].”
InfluentialHallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · cited 1×
“Such findings are frequently reported in bulk tumor transcriptome studies and likely reflect the intricate interplay between malignant cells and the tumor microenvironment (TME) [59–61].”
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“Likewise, the activation of the Wnt/β-catenin/EMT axis accounts for the invasive characteristics we observed, linking this signaling cascade to ccRCC metastasis [34, 35].”
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“As c-Myc and Cyclin D1 are key drivers of cell proliferation, this directly links the PPP1R18/ERK/Wnt/β-catenin axis to the proliferative phenotype of ccRCC [56–58].”
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Cellpose: a generalist algorithm for cellular segmentation
Stringer, C., Wang, T., Michaelos, M., & Pachitariu, M. (2021) · Nature Methods · doi:10.1038/s41592-020-01018-x · Cited by 4,369
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“Based on existing literature, we hypothesize that PPP1R18 may function as a scaffold protein to facilitate Src-mediated activation of the ERK pathway, given that PPP1R18 is a known binding partner of Src, a classic upstream activator of the Ras/Raf/MEK/ERK cascade [18, 21, 38–40].”
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O. J., & Bray, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.005 · Cited by 2,588 · cited 2×
“Owing to the wide-spread adoption of diagnostic imaging, the global incidence of RCC has been steadily increasing, with over 430,000 new cases reported in 2020 [1–6].”
Metadata
- Authors
- Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q.
- Affiliations
- Capital Medical University (CN)
- Peking University (CN)
- Corresponding author
- Fan, Yu
- Zhang, Qian
- Venue
- Cancer Cell International
- Published
- 2026-05-10
- Volume
- 26
- Issue
- 1
- ISSN
- 1475-2867 (ISSN-L)
- PMC
- PMC13340015
- OpenAlex
- W7160765552
- Cited by
- 0
- References
- 64
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 58 d)
- Locations
- Cancer Cell International (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82072826)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- clear cell renal cell carcinoma, Wnt/β-catenin signaling, ERK signaling, epithelial-mesenchymal transition, prognostic factors, oncogenic drivers, tumor cell proliferation, migration and invasion, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma. https://app.cochat.ai/papers/10.1186/s12935-026-04266-7
- The paper
- Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2026). PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma. Cancer Cell International. https://doi.org/10.1186/s12935-026-04266-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.